Pikornavirusten käyttö geenivektoreina ja syöpäterapiassa sekä Coxsackievirus A7 -isolaattien sekvenssianalyysi

Kirjallisessa osassa tarkasteltiin pikornavirusten käyttöä geenivektoreina ja syöpäterapiassa. Pikornavirukset ovat positiivissäikeisiä RNA-viruksia, ja niiden genomi koostuu rakenteellisista kuoriproteiineista VP1-VP4 sekä ei-rakenteellisista proteiineista 2A-2C ja 3A-3D. Geenivektoritutkimukset ovat keskittyneet erilaisten inserttien kloonaamiseen virusten VP1-VP4-alueelle ja genomin 5'-päähän sekä näiden muutosten vaikutusten seuraamiseen virusten elinkierrossa solu- ja hiirimalleissa. Geenivektoreina on parhaiten toimineet coxsackievirukset B3, B4 ja A9 sekä mengo- ja poliovirus. Niitä on käytetty hiirissä mm. neuronien motorisen BDNF-reseptorin ilmentämiseen sekä hiiren interleukiini-10:n tuottamiseen selkäydinkanavan vaurioiden korjaamiseksi. Syöpäterapiatutkimuksissa on saatu lupaavia tuloksia coxsackieviruksilla A21, A13, A15 ja A18 sekä echo-, Seneca Valley 001- ja EMCV-viruksilla. Viruksilla on saatu mm. rintasyövän pääkasvain ja metastasoituneet etäpesäkkeet häviämään sekä eturauhassyövän kasvaimia pienenemään. Seneca Valley 001 -virus on osoittautunut tehokkaaksi syöpiä vastaan, joilla on neuroendokriinisiä ominaisuuksia. Viruksen käyttämistä faasi 2:n kliinisiin kokeisiin ollaan parhaillaan suunnittelemassa pienisoluisen keuhkosyövän ja lasten neuroendokriinisen syövän kohdalla. Kokeellisessa osassa optimoitiin RT-PCR-menetelmä coxsackievirus A7:n (CV-A7) genomin tuottamiseksi PCR-reaktiolla (FL-PCR). FL-PCR:n optimointi tehtiin vektoreilla, joihin oli kloonattu CV-A7-USSR- (USSR-pcDNA3) ja CV-A7-Parkerisolaattien (Parker-TA) genomit. Menetelmää käytettiin myöhemmin muiden CV-A7- virusisolaattien (275/58, ET1080 ja SVK) tutkimiseen. Näistä isolaateista eristettiin virus-RNA, joka käännettiin cDNA:ksi RT-entsyymillä. PCR:ssä käytetyt, CV-A7- spesifiset koettimet oli suunniteltu aiemmin sekvensoidun CV-A7-sekvenssin (GenBank AY421765) pohjalta. Infektiivisen kloonin tuottamiseksi USSR-pcDNA3- ja Parker-TA-vektoreista tuotettiin PCR:n avulla (T7-PCR) virusgenomin sisältävä DNAjakso, jonka 5'-päähän muodostui alukkeiden avulla T7RNA-polymeraasipromoottori ja 3'-päähän polyA-häntä. Työssä myös sekvensoitiin ja analysoitiin CV-A7-virusisolaatit Parker, USSR, 275/58, ET1080 ja SVK sekä kloonattiin täyspitkiä virusgenomeja cDNA-muodossa mutaatiokokeita varten. FL-PCR:n optimointi onnistui, ja neljä viidestä CV-A7-isolaatista sekvensoitiin. Virusgenomien pituus vaihteli 7403–7405 nt:n välillä. CV-A7-ET1080, -Parker ja - USSR osoittautuivat yli 99 % ja CV-A7-275/58 82,6 % nt samankaltaisiksi koko genomin pituudelta AY421765:en suhteen. Yksittäisten geenien ja proteiinien osalta CV-A7-275/58 oli 75,8–90,4 % nt ja 93,7–98,8 % aa samankaltainen muiden suhteen. Simplot-analyysissä 3B-geenialue oli heterogeenisin. CV-A7-SVK-isolaatti osoittautui echovirus kolmeksi. Infektiivistä kloonia ei saatu tuotettua T7-PCR-tuotteista.

JNK, a versatile regulator of kinesin-1 transport and cytoskeleton dynamics

C-Jun N-terminal kinase (JNK) is traditionally recognized as a crucial factor in stress response and inducer of apoptosis upon various stimulations. Three isoforms build the JNK subfamily of MAPK; generally expressed JNK1 and JNK2 and brain specific JNK3. Degenerative potency placed JNK in the spotlight as potential pharmacological option for intervention. Unfortunately, adverse effects of potential drugs and observation that expression of only JNK2 and JNK3 are induced upon stress, restrained initial enthusiasm. Notably, JNK1 demonstrated atypical high constitutive activity in neurons that is not responsive to cellular stresses and indicated existence of physiological activity. This thesis aimed at revealing the physiological functions of JNK1 in actin homeostasis through novel effector MARCKS-Like 1 (MARCKSL1) protein, neuronal trafficking mediated by major kinesin-1 motor protein and microtubule (MT) dynamics via STMN2/SCG10. The screen for novel physiological JNK substrates revealed specific phosphorylation of C-terminal end of MARCKSL1 at S120, T148 and T183 both ex vivo and in vitro. By utilizing site-specific mutagenesis, various actin dynamics and migrations assays we were able to demonstrate that JNK1 phosphorylation specifically facilitates F-actin bundling and thus filament stabilisation. Consecutively, this molecular mechanism was proved to enhance formation of filopodia; cell surface projections that allow cell sensing surrounding environment and migrate efficiently. Our results visualize JNK dependent and MARCKSL1 executed induction of filopodia in neurons and fibroblast indicating general mechanism. Subsequently, inactivation of JNK action on MARCKSL1 shifts cellular actin machinery into lamellipodial dynamic arrangement. Tuning of actin cytoskeleton inevitably melds with cell migration. We observed that both active JNK and JNK pseudo-phosphorylated form of MARCKSL1 reduce actin turnover in intact cells leading to overall diminished cell motility. We demonstrate that tumour transformed cells from breast, prostate, lung and muscle-derived cancers upregulate MARCKSL1. We showed on the example of prostate cancer PC-3 cell line that JNK phosphorylation negatively controls MARCKSL1 ability to induce migration, which precedes cancer cell metastasis. The second round of identification of JNK physiological substrates resulted in detection of predominant motor protein kinesin-1 (Kif5). Mass spectrometry detailed analysis showed evident endogenous phosphorylation of kinesin-1 on S176 within motor domain that interacts with MT. In vitro phosphorylation of bacterially expressed kinesin heavy chain by JNK isoforms displayed higher specificity of JNK1 when compared to JNK3. Since, JNK1 is constitutively active in neurons it signified physiological aspect of kinesin-1 regulation. Subsequent biochemical examination revealed that kinesin-1, when not phosphorylated on JNK site, exhibits much higher affinity toward MTs. Expression of the JNK non-phosphorable kinesin-1 mutant in intact cells as well as in vitro single molecule imaging using total internal reflection fluorescence microscopy indicated that the mutant loses normal speed and is not able to move processively into proper cellular compartments. We identify novel kinesin-1 cargo protein STMN2/SCG10, which along with known kinesin-1 cargo BDNF is showing impaired trafficking when JNK activity is inhibited. Our data postulates that constitutive JNK activity in neurons is crucial for unperturbed physiologically relevant transport of kinesin-1 dependant cargo. Additionally, my work helps to validate another novel physiological JNK1 effector STMN2/SCG10 as determinant of axodendritic neurites dynamics in the developing brain through regulation of MT turnover. We show successively that this increased MT dynamics is crucial during developmental radial migration when brain layering occurs. Successively, we are able to show that introduction of JNK phosphorylation mimicking STMN2/SCG10 S62/73D mutant rescues completely JNK1 genetic deletion migration phenotype. We prove that STMN2/SCG10 is predominant JNK effector responsible for MT depolymerising activity and neurite length during brain development. Summarizing, this work describes identification of three novel JNK substrates MARCKSL1, kinesin-1 and STMN2/SCG10 and investigation of their roles in cytoskeleton dynamics and cargo transport. This data is of high importance to understand physiological meaning of JNK activity, which might have an adverse effect during pharmaceutical intervention aiming at blocking pathological JNK action.

Intracranial Nimodipine Implant: Feasibility and Implications for the Treatment of Subarachnoid Hemorrhage – A Pre-Clinical Study

Intracranial aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening condition requiring immediate neurocritical care. A ruptured aneurysm must be isolated from arterial circulation to prevent rebleeding. Open surgical clipping of the neck of the aneurysm or intra-arterial filling of the aneurysm sack with platinum coils are major treatment strategies in an acute phase. About 40% of the patients suffering from aSAH die within a year of the bleeding despite the intensive treatment. After aSAH, the patient may develop a serious complication called vasospasm. Major risk for the vasospasm takes place at days 5–14 after the primary bleeding. In vasospasm, cerebral arteries contract uncontrollably causing brain ischemia that may lead to death. Nimodipine (NDP) is used to treat of vasospasm and it is administrated intravenously or orally every four hours for 21 days. NDP treatment has been scientifically proven to improve patients’ clinical outcome. The therapeutic effect of L-type calcium channel blocker NDP is due to the ability to dilate cerebral arteries. In addition to vasodilatation, recent research has shown the pleiotropic effect of NDP such as inhibition of neuronal apoptosis and inhibition of microthrombi formation. Indeed, NDP inhibits cortical spreading ischemia. Knowledge of the pathophysiology of the vasospasm has evolved in recent years to a complex entity of early brain injury, secondary injuries and cortical spreading ischemia, instead of being pure intracranial vessel spasm. High NDP levels are beneficial since they protect neurons and inhibit the cortical spreading ischemia. One of the drawbacks of the intravenous or oral administration of NPD is systemic hypotension, which is harmful particularly when the brain is injured. Maximizing the beneficial effects and avoiding systemic hypotension of NDP, we developed a sustained release biodegradable NDP implant that was surgically positioned in the basal cistern of animal models (dog and pig). Higher concentrations were achieved locally and lower concentrations systemically. Using this treatment approach in humans, it may be possible to reduce incidence of harmful hypotension and potentiate beneficial effects of NDP on neurons. Intracellular calcium regulation has a pivotal role in brain plasticity. NDP blocks L-type calcium channels in neurons, substantially decreasing intracellular calcium levels. Thus, we were interested in how NDP affects brain plasticity and tested the hypothesis in a mouse model. We found that NDP activates Brain-derived neurotrophic factor (BDNF) receptor TrkB and its downstream signaling in a reminiscent of antidepressant drugs. In contrast to antidepressant drugs, NDP activates Akt, a major survival-promoting factor. Our group’s previous findings demonstrate that long-term antidepressant treatment reactivates developmental-type of plasticity mechanisms in the adult brain, which allows the remodeling of neuronal networks if combined with appropriate rehabilitation. It seems that NDP has antidepressant-like properties and it is able to induce neuronal plasticity. In general, drug induced neuronal plasticity has a huge potential in neurorehabilitation and more studies are warranted.